Drugs / Abequolixron
Abequolixron
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05911308 | Apr → Oct 2024 | non-small cell lung carcinoma | UNC Lineberger Comprehensive Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT02922764 | Nov 2016 → Jan 2025 | endometrial cancer, non-small cell lung carcinoma | Inspirna, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2023-01-05 | Inspirna, Inc. | Results Inspirna Announces Interim Data from Phase 1b/2 Study of Abequolixron (RGX-104) in Relapsed or Refractory Lung Cancer inspirna.com ↗
Abequolixron in combination with docetaxel in heavily-pretreated NSCLC and SCLC is well tolerated and demonstrates encouraging preliminary clinical activity |
| 2020-06-22 | Inspirna, Inc. | Results RGENIX Presents Biomarker and Efficacy Results from Phase 1 Dose Escalation Cohorts of RGX-104 at the 2020 AACR Annual Meeting inspirna.com ↗
As outlined in the presentation, objective clinical activity was observed in all treatment arms, including the monotherapy ar |
| 2020-04-27 | Inspirna, Inc. | Results RGENIX Presents Initial Results of Combination Trial of RGX-104 at the 2020 AACR Annual Meeting inspirna.com ↗
The results support further development of this regimen. |
| 2018-06-04 | Inspirna, Inc. | Results Rgenix Presents Data on Phase I Clinical Activity For RGX-104 at the 2018 ASCO Annual Meeting inspirna.com ↗
RGX-104 shown to be well-tolerated and capable of generating immunologic and anti-tumor activity in advanced cancer patients. |
| 2018-01-11 | Inspirna, Inc. | Results Rgenix Announces Publication In Cell Demonstrating Activation of LXR/ApoE with RGX-104 Enhances Antitumor Immunity inspirna.com ↗
RGX-104 was able to deplete MDSCs both in cancer patients participating in the dose escalation portion of the Phase 1a/b trial and in mice. |
| 2017-11-17 | Inspirna, Inc. | Results Rgenix Reports Phase I Data for Cancer Compound RGX-104 inspirna.com ↗
Rgenix Inc. (New York, N.Y.) reported preliminary data from a Phase Ia/Ib trial showing that oral RGX-104 led to 4 cases of stable disease among 12 evaluable patients with advanced solid malignancies and lymphoma. |
| 2017-10-30 | Inspirna, Inc. | Results Rgenix Reports Preliminary Phase 1a/b Clinical Data Demonstrating Immune-stimulatory Activity with RGX-104 in Advanced Cancer Patients inspirna.com ↗
These data demonstrate immune-stimulatory activity in solid tumor patients with highly-refractory malignancies, including patients who have failed prior checkpoint inhibitors. |
| 2017-10-29 | Inspirna, Inc. | Results Rgenix Reports Preliminary Phase 1a/b inspirna.com ↗
These data demonstrate immune-stimulatory activity in solid tumor patients with highly-refractory malignancies, including patients who have failed prior checkpoint inhibitors. |
All press releases naming this drug 13 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Abequolixron | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05911308 ↗ |
| Known as | RGX-104 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02922764 ↗ |
| Known as | SB-742881 | ChEMBL registry synonym — accepted as the source's own label CHEMBL573677 ↗ |
| Action | Activate | “RGX-104 activates LXR” NCT02922764 ↗ |
| Modality | Small molecule | “RGX-104, an oral small molecule targeting the liver X receptor (LXR)” NCT02922764 ↗ |
| Route | Oral | “oral small molecule targeting the liver X receptor (LXR)” NCT02922764 ↗ |